New data corroborates value of early intervention for BRVO

New data corroborates value of early intervention for BRVO
brynskov Findings from exploratory analyses of data collected in the BRIGHTER study support initiating anti-VEGF treatment for branch retinal vein occlusion (BRVO) early in order to optimise functional outcomes. “These data are not definite proof of the benefit of early treatment, because that would require a randomised study,” said Ramin Tadayoni MD, PhD, of Sorbonne Paris Cité, Paris, France, at the 16th EURETINA Congress in Copenhagen. “However, they come as supplementary information from a large study showing that treating BRVO patients with higher best corrected visual acuity (BCVA) and earlier leads to better results,” said Dr Tadayoni. BRIGHTER was a 24-month study randomising 455 patients to ranibizumab (Lucentis), ranibizumab plus laser, or laser with ranibizumab allowed after six months. Among patients receiving ranibizumab from baseline, patients with lower baseline BCVA had greater BCVA gains at 24 months than those with a higher baseline BCVA, but a lower final BCVA. Final BCVA also seemed lower in the group where ranibizumab was delayed for at least six months, particularly for those with higher baseline BCVA. Comparing patients after stratification by interval since BRVO showed the BCVA results were poorer for patients with a disease duration ≥12 months versus <12 months. Interestingly, the median time to gain ≥15 letters after initiating ranibizumab was significantly shorter for patients with a shorter duration of BRVO. “These data indicate that one should not give up early when treating patients with longer BRVO duration, because it may take a longer time to evaluate the treatment effect,” said Dr Tadayoni.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...